DRUG-INDUCED LEUKOPENIA

LITERATURE REVIEW
STUDIES
YEARS STUDIES DESIGN OUTCOME
Gisbert et al. 2008 Systematic
review, metaanalysis
Higgs et al. 2010 Systematic
review, metaanalysis
The incidence rate (per patient and year
of treatment) of the drug-induced
myelotoxicity was 3% in IBD patient. Bone
marrow toxicity occur more frequently
during first month.
Individuals with both intermediate and
absent Thiopurine-S-methyltransferase
activity have an increased risk of
developing thiopurine-induced
myelosuppression compared with
individuals with normal activity.
Hadda et al. 2009 Case Report Azathioprine-induced pancytopenia was
suspected in patient treated for lupus
nephritis.
24) Gisbert JP, Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103(7):1783-800
25) Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2010;11:177-88
26) Hadda V, Pandey BD, Gupta R, Goel A. Azathioprine induced pancytopenia: A serious complication. J Postgrad Med [serial online] 2009 [cited 2012 Jan 9];55:139-40. Available from:
URL:http://www.jpgmonline.com/text.asp?2009/55/2/139/52849